Cartesian Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.90 | -$0.90 | -$0.90 |
| Q2 2024 | 1 | -$0.89 | -$0.89 | -$0.89 |
| Q3 2024 | 1 | -$0.86 | -$0.86 | -$0.86 |
| Q4 2024 | 1 | -$0.80 | -$0.80 | -$0.80 |
| Q1 2025 | 4 | -$1.07 | -$0.62 | -$0.80 |
| Q2 2025 | 2 | -$0.74 | -$0.74 | -$0.74 |
| Q3 2025 | 1 | -$0.81 | -$0.81 | -$0.81 |
| Q4 2025 | 1 | -$0.89 | -$0.89 | -$0.89 |
| Q1 2026 | 1 | -$1.00 | -$1.00 | -$1.00 |
Cartesian Therapeutics, Inc. Earnings Date And Information
Cartesian Therapeutics, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.69 earnings per share for the quarter, topping analysts' consensus estimates of $-0.78 by $0.09. The company had revenue of 5.84 M for the quarter and had revenue of 26.00 M for the year. Cartesian Therapeutics, Inc. has generated $-42 earnings per share over the last year ($-42.49 diluted earnings per share) and currently has a price-to-earnings ratio of -0.39. Cartesian Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 6th, 2025 based on prior year's report dates.
Cartesian Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/08/2024 | Q1 2024 | -$0.81 | -$10.50 | -9.69 | $1.67 M | $5.84 M |
| 12/30/2023 | Q4 2023 | -$34.43 | $8.27 M | |||
| 09/29/2023 | Q3 2023 | -$1.74 | $5.60 M | $6.55 M | ||
| 06/29/2023 | Q2 2023 | -$2.23 | $12.14 M | $5.25 M | ||
| 03/30/2023 | Q1 2023 | -$4.24 | $5.94 M | |||
| 12/29/2022 | Q4 2022 | $1.16 | $16.80 M | |||
| 09/28/2022 | Q3 2022 | -$1.55 | $13.78 M | $20.71 M | ||
| 06/28/2022 | Q2 2022 | $1.74 | $12.14 M | $39.27 M | ||
| 03/29/2022 | Q1 2022 | $6.95 | $34.00 M | |||
| 12/29/2021 | Q4 2021 | $3.12 | $29.94 M | |||
| 09/28/2021 | Q3 2021 | -$4.66 | $7.13 M | $24.43 M | ||
| 06/28/2021 | Q2 2021 | $1.21 | $6.27 M | $19.66 M | ||
| 03/29/2021 | Q1 2021 | -$6.66 | $11.05 M |
Cartesian Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Cartesian Therapeutics, Inc.'s earnings date?
Cartesian Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 6th, 2025 based off last year's report dates.
-
Did Cartesian Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Cartesian Therapeutics, Inc. (:RNAC) reported $-0.69 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.78 by $0.09.
-
How can I listen to Cartesian Therapeutics, Inc.'s earnings conference call?
The conference call for Cartesian Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Cartesian Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Cartesian Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Cartesian Therapeutics, Inc. generate each year?
Cartesian Therapeutics, Inc. (:RNAC) has a recorded annual revenue of $26.00 M.
-
How much profit does Cartesian Therapeutics, Inc. generate each year?
Cartesian Therapeutics, Inc. (:RNAC) has a recorded net income of $26.00 M. Cartesian Therapeutics, Inc. has generated $-42.49 earnings per share over the last four quarters.
-
What is Cartesian Therapeutics, Inc.'s price-to-earnings ratio?
Cartesian Therapeutics, Inc. (:RNAC) has a price-to-earnings ratio of -0.39 and price/earnings-to-growth ratio is 0.03.
